For NSCLC, EGFR mutations and on abnormal fusion of ALK being targeted successfully with EGFR tyrosine kinase inhibitors (TKI) and ALK inhibitors respectively. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.